MedTrace Logo

Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT00693238 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2023-09-18

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.

Conditions

Interventions

RADIATION

Low Risk Proton Radiation

RADIATION

Intermediate Risk Proton Radiation

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Randal H Henderson, MD · University of Florida

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-06-30
Completion
2022-04-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693238 on ClinicalTrials.gov